XML 52 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments (Summary Of The Effect Of Derivative Instruments On The Consolidated Statements Of Changes In Equity And Income) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Amount of Gain (Loss) Recognized in AOCI on Derivative (Effective Portion) $ (3,947) $ 2,061 $ (7,966) $ (11,163)
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 141 139 475 423
Amount of Income (Expense) Reclassified from AOCI into Earnings (Effective Portion) (2,024) 309 (3,648) 1,778
Interest Expense 41,744 36,667 114,837 107,088
Other Income 182 11,464 8,171 17,534
Interest Rate Swap [Member]        
Amount of Income (Expense) Reclassified from AOCI into Earnings (Effective Portion) [1] (2,037) 174 (4,103) 1,352
Cross Currency Swaps [Member]        
Amount of Gain (Loss) Recognized in AOCI on Derivative (Effective Portion) (243) 134 424 (342)
Amount of Income (Expense) Reclassified from AOCI into Earnings (Effective Portion) [2] 13 135 455 426
Cross Currency Swap 2023 [Member]        
Amount of Gain (Loss) Recognized in AOCI on Derivative (Effective Portion) (3,827) 3,033 3,160 (1,863)
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net [2] 141 [3] 139 [3] 475 423
Interest Expense [Member] | Interest Rate Swap [Member]        
Amount of Gain (Loss) Recognized in AOCI on Derivative (Effective Portion) $ 123 $ (1,106) $ (11,550) $ (8,958)
[1] (1) Included in "Interest expense, net" in the accompanying consolidated statements of (loss) income and comprehensive (loss) income for the three and nine months ended September 30, 2020 and 2019.
[2] (2) Included in "Other income" in the accompanying consolidated statements of (loss) income and comprehensive (loss) income for the three and nine months ended September 30, 2020 and 2019.
[3] (3) Amounts represent derivative gains excluded from the effectiveness testing.